Drug Trial Radar · NCT03128164
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Aug 8, 2017
Primary completion
Aug 2, 2023
Study completion Aug 2, 2023
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).
Conditions
- Lymphomas
Interventions
HMPL-689Drug
Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicities evaluated with NCI CTCAE v4.03Time frame: within 28 days after the first dose
- Objective response rate (ORR)Time frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University cancer center
Guangzhou, China
Fudan University Shanghai Cancer Center
Shanghai, China
TongJi Medical College Huazhong University of Science& Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.